Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

On Thursday, Moderna Inc. MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion.The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.BofA Securities notes that Moderna’s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company’s respiratory vaccine lineup, as well as new concerns related to Trump and Kennedy’s positions on vacci ...